Establishing the Value of Treatment Strategies in Spondyloarthritis: The ValSpA Study

This work assesses patient preferences related to spondyloarthritis medications through patient focus groups and discrete choice experiments. A subsequent cost-effectiveness model will incorporate patient values with literature-derived estimates for medication effects, side effect rates, and costs. The hypothesis is that more expensive biological agents are not cost-effective as first line therapy for spondyloarthritis.
PI: Maureen Dubreuil
Funded by NIH/NIAMS K23 AR069127. Funding period: 2016-2021